Table 1 Demographics of the entire cohort.
From: Prediction of longitudinal outcomes and novel cluster identification in epilepsy
Number (%) ± standard deviation | SF (N = 1709) | NSF (N = 877) | |
|---|---|---|---|
Sex (female: male) | 1191:1395 | ||
(46.1%: 53.9%) | 757:952 | ||
(44.3%: 55.7%) | 434:443 (49.5%: 50.5%) | ||
Onset age | 29.6 ± 19.6 | 32.4 ± 20.5 | 23.0 ± 16.1 |
Epilepsy duration (years) | 6.8 ± 9.6 | 5.7 ± 8.9 | 9.0 ± 10.6 |
Number of seizures before ASM initiation | 12.3 ± 86.3 | 10.1 ± 49.8 | 18.1 ± 141.7 |
Seizure types | |||
Focal | 2068 (80.0%) | 1314 (76.9%) | 754 (86.0%) |
Generalized | 472 (18.3%) | 355 (20.8%) | 117 (13.3%) |
Unknown | 46 (1.8%) | 40 (2.3%) | 6 (0.7%) |
Epilepsy types | |||
Focal | 1924 (74.4%) | 1231 (72.0%) | 693 (79.0%) |
Generalized | 467 (18.1%) | 349 (20.4%) | 118 (13.5%) |
Combined | 154 (6.0%) | 93 (5.4%) | 61 (7.0%) |
Unknown | 41 (1.6%) | 36 (2.1%) | 5 (0.6%) |
Etiology | |||
Structural | 873 (33.8%) | 537 (31.4%) | 336 (38.3%) |
Genetic | 438 (16.9%) | 329 (19.3%) | 109 (12.4%) |
Immune | 90 (3.5%) | 62 (3.6%) | 28 (3.2%) |
Infectious | 53 (2.0%) | 37 (2.2%) | 16 (1.8%) |
Hypoxic | 5 (0.2%) | 3 (0.2%) | 2 (0.2%) |
Metabolic | 3 (0.1%) | 3 (0.2%) | 0 (0%) |
Unknown | 1124 (43.5%) | 738 (43.2%) | 386 (44.0%) |
History of febrile convulsion ( +) | 171 (6.6%) | 94 (5.5%) | 77 (8.8%) |
Family history of epilepsy ( +) | 76 (2.9%) | 49 (2.9%) | 27 (3.1%) |
